Metformin for Idiopathic Pulmonary Fibrosis
This study is testing if metformin can help slow down the worsening of Idiopathic Pulmonary Fibrosis (IPF), a serious lung disease. Researchers are looking for 800 people with IPF, aged 40 or older, who have a specific "proteomic signature" (a pattern found in blood tests) that suggests they are at high risk for their disease getting worse. If you qualify, you would either receive metformin or a matching placebo (an inactive substance) for 12 to 24 months. The main goal is to see if metformin can reduce the risk of death, unplanned hospital stays, or needing a lung transplant. The study's current status is unclear.
- Study design
- This is a randomized, double-blind study comparing metformin to a placebo in 400 participants with IPF who are at high risk based on a proteomic signature.
- What's involved
- If you have the proteomic signature, you would take metformin or placebo daily, with the dose gradually increasing. You would have follow-up visits at months 1, 3, 6, 12, 18, 24, and a phone call at 25 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for a minimum of 12 months and a maximum of approximately 25 months after starting treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis
At a glance
Conditions
NCT07520110
Where you'd take part
This study runs at 15 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Georgetown University Hospital
Washington D.C., District of Columbiastudy coordinator listed
Massachusetts General Hospital
Boston, Massachusettsstudy coordinator listed
Mayo Clinic
Rochester, Minnesotastudy coordinator listed
Michael E. DeBakey VA Medical Center
Houston, Texasstudy coordinator listed
Northwestern University
Chicago, Illinoisstudy coordinator listed
Temple University
Philadelphia, Pennsylvaniastudy coordinator listed
University of Arizona
Tucson, Arizonastudy coordinator listed
University of Chicago
Chicago, Illinoisstudy coordinator listed
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Fernando Martinez, MD, MS · PRINCIPAL_INVESTIGATOR · UMass Chan Medical School
- Sydney Montesi, MD · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital
- Bhavika Kaul, MD, MAS · PRINCIPAL_INVESTIGATOR · Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC)
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Time to death, non-elective hospitalization, or lung transplantationBaseline (visit 1) to up to 24 months
Clinical composite measure defined as the time from randomization to the first occurrence of any of its three components: all-cause mortality, first unplanned (non-elective) hospitalization, or lung transplantation.